Bluejay Therapeutics has appointed Mary Cromwell, Ph.D., as Senior Vice President and Head of Technical Operations, bringing over 30 years of biotechnology operations experience to advance their liver disease therapeutics pipeline.
The FDA granted Breakthrough Therapy designation to Bluejay Therapeutics' brelovitug for chronic hepatitis delta (CHD), a severe liver disease with no approved treatments in the US.
Bluejay Therapeutics' BJT-778 achieved a 100% virologic response in a Phase 2 study for chronic hepatitis D (CHD) when dosed at 300mg, 600mg and 900mg.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.